|
9th Influenza Conference 2023
The Ninth ESWI Influenza Conference: Highlights
ESWI 2023: 10 key take home messages
International scientific community gathers in Valencia for the 9th ESWI Conference on Influenza, COVID-19, and RSV
Since it was established 30 years ago, the European Scientific Working Group on Influenza and other Acute Respiratory Viruses (ESWI) is hosting the 9TH ESWI Influenza Conference
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
Nirsevimab is a monoclonal antibody that binds to the RSV fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical trials, infants received one dose of nirsevimab or placebo before their first RSV season.
Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers
Antibody levels and neutralizing activity progressively increased with each booster but subsequently waned over 3-6 months.
Subclass-switched anti-spike IgG3 oligoclonal cocktails strongly enhance Fc-mediated opsonization
Is it possible to improve the antibodies that the body produces to fight SARS-CoV2? In a study led by researchers from Lund University in Sweden, this was investigated by redesigning antibodies and combining them against the virus.
Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities
Biotherapeutics, such as recombinant proteins and monoclonal antibodies, have become mainstays of modern medicine as shown by their increasing number in the WHO Model List of Essential Medicines.
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
These new subvariants carrying further mutations in their spike proteins raise concerns that they may further evade neutralizing antibodies.
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years).
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years).
